Needham & Company Starts Collegium Pharmaceutical (COLL) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Piper Jaffray Starts Collegium Pharmaceutical (COLL) at Overweight
June 1, 2015 6:52 AM EDTPiper Jaffray initiates coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Overweight rating and a price target of $26.00.
Analyst David Amsellem commented, "We believe that COLLs DETERx tamper-deterrent platform has the potential to drive dramatic long-term value creation. Xtampza ER, COLLs... More
Jefferies Starts Collegium Pharmaceutical (COLL) at Buy
June 1, 2015 6:44 AM EDTJefferies initiates coverage on Collegium Pharmaceutical (NASDAQ: COLL) with a Buy rating and a price target of $20.00.
Analyst David Steinberg commented, "Collegium (COLL) is an emerging leader in abuse-deterrent extended-release (ER) opioids used for treating chronic pain. COLL is on the cusp of... More
